$Olam Group (VC2.SG)$ 1.13 on paying $3.5 mil to CFTC. Ref: Olam agrees to pay US$3.3 mil in settlement with Commodity Futures Trading Commission

$Cordlife (P8A.SG)$ ref. Cordlife customers push for legal action

$Tesla (TSLA.US)$ usd220.110. Cited production challenge for the unique design,  may take time to reach cash flow positive for Cybertruck, and faced challenges and delays since 2019.
Reference
1. https://www.businessinsider.com/elon-musk-says-cybertruck-faces-enormous-production-challenges-tesla-2023-10

$Pacific Biosciences of California (PACB.US)$ usd 8.04. it was unfortunate that PacBio could not move to profit since 2007. The only time it got surplus was the payment by Illumina for the terminated merger. Sigh.

$Pfizer (PFE.US)$ usd 38.30. Pfizer's lotiglipron dropped, danuglipron still in the test pipeline for obesity drug. Alternative includes Novo Nordisk's Ozempic which is also at mid-stage testing (ref. 1).
Ref
1. https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-discontinue-development-obesity-drug-2023-06-26/

$BioNTech (BNTX.US)$ usd 126.58 2023 sales expected to be lower due to tapering demand for Covid-19 vaccine (ref fiercepharma.com). several lawsuits: This year, Arbutus Biopharma to file patent lawsuit against Pfizer & BioNTech over Covid vaccines (ref. Reuter). In 2022, Moderna and Alnylam respectively sued Pfizer/BioNTech for patent infringement. Any good news? Jan 2023 BioNTech partnered with UK Government to provide patients with personalised mRNA cancer immunotherapies by 203...

$Suntec Reit (T82U.SG)$ sgd 1.34. Concern about tech sector slowdown (constituting approx 40% its leasee), high interest rate, high gearing (i.e., debt-to-equity), 30% lease due for renewal. Good points is high occupancy, long-term leases, forex hedged . Strategy anticipated: divest assets to lower debt (ref. 1)
reference
1. https://www.theedgesingapore.com/capital/brokers-calls/rhb-downgrades-suntec-reit-neutral-lower-tp-147

$Top Glove (BVA.SG)$ sgd 0.215. It is time to reduce the expenses. If covid-driven scaled-up production and its related cost is not permanent, we are safe, else it will be very bad. This is in consideration of the current challenges, i.e., over-supply, increased competition, raw material price hike (e.g., latex, crude oil), minimum wage increase in Malaysia in 2022, and others.
The extraordinary demand may had been du...

$Aspen (1F3.SG)$ sgd 0.042. Not a good performance this time round. That is why its P/L is in red.

$Pacific Biosciences of California (PACB.US)$ usd 5.66. Opex is increasing while revenue followed laggingly. COGS is reasonable though... If revenue can't exceed opex, I don't see any reason to buy unless I hope for surprises or M&A deal.